Our study thus provides a proof-of-concept that circSCMH1 can function as a novel inhibitor of KMO and thus has the potential to be a therapeutic target for efforts to manage metabolic disorders after cerebral ischemia. The gene discussed is KMO; the disease is Cerebral ischemia.